Pulmatrix Inc (PULM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pulmatrix Inc (PULM) has a cash flow conversion efficiency ratio of -0.218x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.03 Million) by net assets ($4.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PULM net asset quality index to measure how much of total assets are equity-financed.
Pulmatrix Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Pulmatrix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Pulmatrix Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Pulmatrix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulmatrix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dynasty Gold Corp
V:DYG
|
0.010x |
|
Carmat
PA:ALCAR
|
0.344x |
|
GD Culture Group Limited
NASDAQ:GDC
|
0.000x |
|
Filtronic
LSE:FTC
|
0.330x |
|
Solis Minerals Ltd
V:SLMN
|
-0.043x |
|
Clinical Laserthermia Systems AB (publ)
ST:CLS-B
|
-0.186x |
|
Mexican Gold Corp
V:MEX
|
0.953x |
|
E Media Holdings Ltd
JSE:EMH
|
0.047x |
Annual Cash Flow Conversion Efficiency for Pulmatrix Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Pulmatrix Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see PULM market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.95 Million | $-10.72 Million | -1.198x | -34.83% |
| 2023-12-31 | $18.00 Million | $-15.98 Million | -0.888x | -42.77% |
| 2022-12-31 | $31.11 Million | $-19.36 Million | -0.622x | -49.66% |
| 2021-12-31 | $47.45 Million | $-19.73 Million | -0.416x | +22.93% |
| 2020-12-31 | $23.14 Million | $-12.48 Million | -0.539x | -284.04% |
| 2019-12-31 | $11.02 Million | $3.23 Million | 0.293x | +120.71% |
| 2018-12-31 | $11.84 Million | $-16.76 Million | -1.415x | +0.91% |
| 2017-12-31 | $10.14 Million | $-14.48 Million | -1.428x | +5.52% |
| 2016-12-31 | $8.76 Million | $-13.24 Million | -1.512x | -295.18% |
| 2015-12-31 | $32.61 Million | $-12.47 Million | -0.383x | -88.47% |
| 2014-12-31 | $14.63 Million | $-2.97 Million | -0.203x | 0.00% |
| 2013-12-31 | $14.63 Million | $-2.97 Million | -0.203x | +97.76% |
| 2012-12-31 | $47.00K | $-426.00K | -9.064x | -- |
About Pulmatrix Inc
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic appli… Read more